Dr. Scott Demarest received a Bachelor of Science in biology from the University of Texas at Austin before going on to medical school at the University of Texas Health Science Center in San Antonio. He completed his residency in Pediatrics and child neurology at Children's National Health System in Washington, DC and his Epilepsy fellowship at Children's Hospital Colorado. His clinical practice and research focus on the evaluation and treatment of early-life genetic epilepsies. Specifically, his research focuses on the characterization of neurogenetic conditions through phenotyping and natural history studies, development of better outcome measures as tools for both natural history studies and clinical trials and the design of disease modifying clinical trial for rare diseases. Additionally, Dr. Demarest is the PI of the International CDKL5 Clinical Research Network (ICCRN). The ICCRN includes eight US institutions and one international site in Australia all working collaboratively to develop clinical trial readiness for disease modifying trials for CDKL5 Deficiency Disorder through improved natural history data for CDKL5 and the development and validation of appropriate outcome measures for CDKL5 Deficiency Disorder.